Search | Clinical Trials Finder

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops; Combination Product · Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more

Conditions: Glaucoma
Interventions: Cosopt (combination eyedrop of dorzolamide and timolol); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Glaucoma
Interventions: Latanoprost, Dorzolamide, Timolol; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: timolol hemihydrate, timolol maleate; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Normal Tension Glaucoma (NTG)
Interventions: QLS-101, Timolol maleate PF 0.5% ophthalmic solution; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Ocular Hypertension
Interventions: brimonidine/timolol fixed combination; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Glaucoma
Interventions: Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Glaucoma, Ocular Hypertension
Interventions: BETOPTIC S (betaxolol HCl), Timolol Gel-forming Solution (TGFS); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Week to 5 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 56
States / cities: Phoenix, Arizona • Glendale, California • Irvine, California + 51 more

Conditions: Open Angle Glaucoma
Interventions: Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Prairie Eye Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Mohs Micrographic Surgery, Excision Margin
Interventions: Timolol 0.5% Ophthalmic Solution, Hydrogel of placebo; Drug · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Sacramento, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo; Drug
Lead sponsor: Othera Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: QLS-101, Timolol Maleate; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Albany, Georgia

Conditions: Glaucoma
Interventions: timolol maleate and dorzolamide hydrochloride; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Exfoliation Syndrome, Glaucoma, Ocular Hypertension
Interventions: Latanoprost with Pilocarpine vs Timolol or Cosopt; Drug
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 50 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Hole, Retinal Detachment
Interventions: Dorzolamide 2%-timolol 0.5% topical eyedrops; Drug
Lead sponsor: Mid Atlantic Retina; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Interventions: timolol maleate, dorzolamide/timolol maleate fixed combination; Drug
Lead sponsor: Pharmaceutical Research Network; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Little Rock, Arkansas • Atlanta, Georgia • Bourbonnais, Illinois + 2 more

Search by objective public record fields.

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions

Circadian Rhythms of Aqueous Humor Dynamics in Humans

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Stop Retinal Ganglion Cell Dysfunction Study

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses

The International Collaborative Exfoliation Syndrome Treatment Study

Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Assessing Cosopt Switch Patients